Tyler Crowe

Yeah, and to that point, too, like to Lou, like you were saying, you know, not necessarily the biggest fans of Andrew Leff, but Citron Research were some of the first ones to point out with all the accounting shenanigans that were going on at Valiant Pharmaceuticals.

I think it was back in 2015.

I think within days of that Citron Research report, Valiant was making drastic changes to its business, you know, talking about...

disassociating itself from some of the pharmacies that it was working with because there was accusations that they were using those pharmacies for overcharging.

It was a pretty clear-cut fraud case that Citron brought to everyone's attention here.

It was good and important work.

And to your point, Matt, Nicola was a great one.

And while this technically wasn't a short report, John Carey's work on Theranos was in that same spirit.

I mean, I think...

Had Theranos gone public without some of that work, I'm sure they would have made it even worse.

We, the market, we sometimes need people on the lookout for the bad stuff, for the valiance, for the Nicholas and stuff like that.

Otherwise, they can perpetuate and get even worse.

With all of that said, and this is where it starts to get conflicting, there is something that's definitely icky about the business model for many short sellers.

And the verdict during this Citron Research court decision is where some of that icky business practices started to come to light.

And I think that's why we're kind of like, I don't really know if I want to stand up for Andrew Left here, right?

You know, I'm going to do a shameless plug here for The Motley Fool because, hey, you know what?

It's our podcast.

I get to do that sometimes.

Like, you know, we get some stocks right.

We get some stocks wrong.